Diagnostic & Services

  • 2:38 PM

    On Wednesday, after market closed, Rocky Mountain Dealerships posted second quarter EPS of $0.32, which was ahead of consensus and our forecast of $0.25. The beat was mainly as a result of higher gross margin (shift in sales mix) and a lower SGeneral and Administrative expense rate. Reported revenue of $243 million was in-line with

    Read more
  • 11:38 PM

    On Thursday, before market opened, Great-West Lifeco reported solid second quarter with core EPS of $0.63, an boost of 15% year-over-year – which remained in line with our and consensus estimates of $0.63. Earnings growth was led by a 24% raise in anticipated profit, strong underwriting results and a 36% boost in total AUA to

    Read more
  • 7:33 PM

    Boston Scientific (BSX, Neutral) launches 25 mm Lotus Transcatheter Aortic Valve Implantation (TAVI) System and commences its commercial launch in Europe after getting CE Mark clearance. On top of it, company reported mixed second quarter results which were above consensus expectations. Revenue of $1.87 billion was nearly in-line with our estimates but recorded at least

    Read more
  • 8:37 AM

    Kimco Realty (KIM, Outperform)’s strategy of simplicity and changes/upgrade of portfolio by concentrating on high quality assets and reducing joint ventures – resulted into another successful quarter. Kimco purchased 10 shopping centers from JV partner SEB Asset Management in Mid-Atlantic area for $275.8 million. In second quarter, revenue of $260.24 million increased by 14.6%, beating

    Read more
  • 8:27 AM

    WestJet Airlines (WJAFF, Buy)’ operations are running on the strategy that trusted staffs provide high quality of service to customers and contented passengers will lead shareholder returns. The company posted net profit of C$51.8 million (40 Canadian cents per share) in second quarter beating the consensus estimate of $0.28 by $0.12. Canadian airline flies high

    Read more
  • 11:46 PM

    Thoratec (NASDAQ: THOR) has acquired Apica Cardiovascular Limited (“Apica”) for an upfront cash payment of $35 million and potential future clinical and sales milestones of up to $40 million. As part of the agreement, the Apica team based at facilities in Ireland and the United States will transition to Thoratec. Apica has developed a suite

    Read more